Published in Bioorg Med Chem on April 24, 2007
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev (2016) 1.02
Recent Progress on the Stereoselective Synthesis of Cyclic Quaternary alpha-Amino Acids. Tetrahedron Asymmetry (2009) 0.95
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.95
The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci (2012) 0.94
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 0.93
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives. Br J Pharmacol (2014) 0.87
Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2. PLoS One (2015) 0.83
Central N/OFQ-NOP Receptor System in Pain Modulation. Adv Pharmacol (2015) 0.82
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Pre-procedural fasting for coronary interventions: is it time to change practice? Heart (2014) 2.61
Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS One (2012) 2.23
Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem (2002) 1.99
Sensory integration and the perceptual experience of persons with autism. J Autism Dev Disord (2006) 1.95
The tachykinin peptide family. Pharmacol Rev (2002) 1.82
CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res (2005) 1.72
The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem (2006) 1.70
Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol (2009) 1.70
A review of mathematical models used to determine sperm donor limits for infertility treatment. Fertil Steril (2007) 1.50
Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov (2004) 1.44
Dmt and opioid peptides: a potent alliance. Biopolymers (2003) 1.40
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A (2009) 1.24
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem (2002) 1.23
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.14
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol (2002) 1.14
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Interaction of sweet proteins with their receptor. A conformational study of peptides corresponding to loops of brazzein, monellin and thaumatin. Eur J Biochem (2004) 1.11
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev (2010) 1.09
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther (2007) 1.09
Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation (2002) 1.08
Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides (2008) 1.08
Lack of "immunological fitness" during fasting in metabolically challenged animals. J Lipid Res (2012) 1.08
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci (2005) 1.06
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides (2007) 1.05
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol (2004) 1.04
Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem (2004) 1.04
Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy? J Pharmacol Exp Ther (2003) 1.03
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev (2005) 1.01
Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol (2004) 1.00
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00
Solution structure of ZASP PDZ domain; implications for sarcomere ultrastructure and enigma family redundancy. Structure (2004) 0.99
Exonization of the LTR transposable elements in human genome. BMC Genomics (2007) 0.99
Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem (2008) 0.99
The C-terminal tail of the M3-muscarinic receptor possesses anti-apoptotic properties. J Biol Chem (2003) 0.98
Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain (2003) 0.98
Inflammation in the uterus induces phosphorylated extracellular signal-regulated kinase and substance P immunoreactivity in dorsal root ganglia neurons innervating both uterus and colon in rats. J Neurosci Res (2008) 0.98
In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant. Peptides (2012) 0.97
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem (2006) 0.97
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides (2010) 0.97
Activation of DOR attenuates anoxic K+ derangement via inhibition of Na+ entry in mouse cortex. Cereb Cortex (2008) 0.96
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. J Med Chem (2004) 0.96
Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem (2004) 0.96
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96